There seems to be a lot of confusion over Anavex's patent – what I see from the uspto is a patent application that was; filed on: March 12, 2014 for Inventor: Vamvakides, Alexandre assigned to: Anavex Life Sciences Corp granted/issued on: November 10, 2015 patent no.: 9,180,106
Abstract The present invention involves new and original sigma receptors ligands: (Mono- or dialkylaminoalkyl)-.gamma.-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl)benzene alkylamines, the N,N Dialkyl .alpha.-[(adamantyl-1)benzyloxy-2]alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or -alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.
The patent expires 20 years from the filing date, so 2014 + 20 = 2034
News 
Market Data 
Discover 
